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The efﬁcacy of scarce drugs for many infectious diseases is threatened by the emergence and spread of
resistance.Multiple studies show that available drugs should beused in a socially optimalway to contain drug
resistance. This paper studies the tradeoff between risk of drug resistance and operational costs when using
multiple drugs for a speciﬁc disease. Using a model for disease transmission and resistance spread, we show
that treatmentwithmultipledrugs, onapopulation level, results inbetter resistance-relatedhealthoutcomes,
but more interestingly, the marginal beneﬁt decreases as the number of drugs used increases. We compare
this beneﬁt with the corresponding change in procurement and safety stock holding costs that result from
higher drug variety in the supply chain. Using a large-scale simulation based on malaria transmission dy-
namics,we show thatdiseaseprevalence seems tobea less important factorwhendeciding the optimalwidth
of drug assortment, compared to the duration of one episode of the disease and the price of the drug(s) used.
Our analysis shows that under awide variety of scenarios for disease prevalence and drug cost, it is optimal to
simultaneously deploy multiple drugs in the population. If the drug price is high, large volume purchasing
discounts are available, and disease prevalence is high, it may be optimal to use only one drug. Our model
lends insights to policy makers into the socially optimal size of drug assortment for a given context.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY license.1. Introduction [26]. Major investments in drug development can be undermined ifResistance against existing drugs is an extremely serious prob-
lem that undermines effective health care for millions of people
[32,33]. The regulation and use of available drugs as well as the
behavior of individuals and institutions strongly inﬂuence the
evolution of resistance. In the absence of suitable economic in-
centives, decision makers (such as governments, physicians, pa-
tients) fail to take into account the negative impact of their policies
or use of drugs on the future effectiveness of these products [42].
Even if the emergence of resistance to drugs is a naturally occurring
biological phenomenon, this process may be accelerated or delayed
by many factors one of the most important being the drug treat-
ment strategies and policies implemented in different countriesE. Spiliotopoulou), mboni@
r Ltd. Open access under CC BY license.therapies lose efﬁcacy due to inappropriate drug use; inappropriate
use anywhere can generate drug resistance with implications for
patients everywhere. The history of drug-resistance evolution in
malaria is an instructive example. In the 1950s, resistance to chlo-
roquine e the most commonly used antimalarial at the time -
emerged in several locations and spread globally over the next two
decades [38,41]. This led to the widespread adoption of antifolate
drugs, and resistance to these drugs emerged shortly therafter [38].
This pattern is on the verge of being repeated for artemisinin-based
drugs, the current globally used ﬁrst-line therapy against malaria
[19,22,34]. The use of multiple ﬁrst line treatments for malaria re-
mains almost nonexistent, partially because of concerns about
higher programmatic and supply chains costs. The lack of rigorous
analysis comparing the beneﬁts and operational costs of using
multiple drugs is contributing to global policy inaction on this issue.
In response to concerns about the evolution of drug resistance
and the global health threat that its spread poses, many mathe-
matical modeling studies have tried to understand the impact of
using multiple therapies simultaneously in a population on the
emergence and spread of drug resistance [5e8,10]. These studies
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neously in the population, the emergence of drug resistance is
delayed and its evolution is slowed. This is mainly due to a) the
decrease in short-term and long-term drug-speciﬁc selection
pressure resulting from the high number of available drugs and b)
the slower degradation of the mean ﬁtness of the parasite popu-
lation, making it more difﬁcult for new resistant types to invade
and spread. In addition, the policy of using multiple drugs at the
same time allows larger fraction of the population to be treated
without trading off against future treatment of cases that may be
untreatable due to high resistance levels.
While these studies show that increasing drug variety delays the
emergence and spread of drug resistance, increased drug variety
comes with additional operational costs. Volume discounts are a
common practice in the pharmaceutical sector, implying that using
more types of drugs for the samediseasewould result in a higher per
unit price for the sourced drugs. Also, when demand is uncertain,
wider drug variety for a speciﬁc disease implies higher safety stocks
and therefore higher inventory holding costs. On the other hand,
when all patients are treated with the same drug, there is a demand
variability pooling effect that allows one to hold less safety stock in
order to achieve the same customer (patient) service level (proba-
bility of stock-out during replenishment). For a given number of
sourced treatments, increased drug variety leads to higher cost of
procuring the drugs, increased inventory holding costs and in some
cases may lead to increased healthcare worker training costs. This
paper studies the tradeoff between risk of drug resistance and
operational costs when using multiple drugs for a speciﬁc disease.
In this paper, we quantify the beneﬁt of delayed resistance and
disease containment associated with drug variety and compare it
against the cost of higher variety in the supply chain. Our model
lends insights to policy makers into the socially optimal size of the
drug assortment. The rest of the paper is organized as follows: in
section 2, we review the relevant literature in pharmaceutical eco-
nomics and policy, epidemiology and supply chain management. In
section 3, we employ a disease model that includes the emergence
and evolution of resistance, we deﬁne disease burden using the
concept of (Disability Adjusted Life Years) DALY, and by performing
simulation analysis we show that disease prevalence and total
resistance both decrease, in cumulative terms, with the number of
drugsused. In section4,westudy together thedirectional effects of a
wider drug assortment with respect to disease and resistance
containment and procurement and safety stock holding costs. We
complement the analysis by an extensive numerical study in section
5. In section 6, we summarize our results and present some policy
insights regarding the socially optimal width of drug assortment.
2. Related literature
The ﬁeld of pharmacoeconomics is concernedwith optimal drug
use. Issues of cost effectiveness are increasingly being placed
alongside issues of clinical effectiveness in determining the desir-
ability of introducing new drugs, especially given the rapid growth
in drug expenditures combined with the ever increasing pressure
to control healthcare expenditure [40]. Walley et al. [40] present
methods of economic evaluation in relation to medicines [36],
employs an economic framework to examine separately the supply
and demand sides of the pharmaceutical market and [39] examines
health public policy from a theoretical perspective employing
economic theory.
Most of the literature that currently exists on the subject of
antibiotic resistance is largely within the biological and medical
science literature; optimal drug use has been addressed within an
economic context by only a few researchers. Among the most
notable papers that have dealt with the economic considerationssurrounding biological resistance have been those of [11,25]. The
ﬁrst uses a very general analytical framework about both agricul-
tural and human drug use, giving more attention to the private
versus public aspect of the problem. The latter is among the ﬁrst to
recast an epidemiological model of antibiotic-resistant disease
within an economic framework that considers the economic costs
and beneﬁts of treatment. Laxminarayan and Weitzman [27]
consider the problem of optimal drug combination, recognizing
the resistance problem associated with the uniform use of a single
drug. They argue that a policy of uniform treatment of all patients
based on the standard cost-effectiveness criterion may be inappro-
priate when drug resistance is endogenous, and selection pressure
imposed by the use of any single drug leads sooner or later to the
evolution of resistance to that drug. They consider resistance an
externality that should be taken into account when socially optimal
drug combination policy is considered. They show that a mixed
treatment policy of multiple drug use is generally desirable. They
assume that all patients receive treatment, effectiveness of all drugs
is identical but their prices vary considerably.
Laxminarayan [23] attempts to bring together a variety of ap-
proaches to the economics of resistance by assembling papers in this
emerging ﬁeld of study. The book focuses on the use of economic
tools to characterize the efﬁcient use of antibiotics in the face of
resistance as well as on the economic impact of resistance and de-
cision making under uncertainty about future resistance. It also dis-
cusses how regulatory incentives might be structured for the
pharmaceutical industry. Besides the theoretical and empirical work
about drug resistance, its development, magnitude, key drivers and
policyconsiderations [28]; CGDs [2,17], there hasbeensomeefforts to
model the evolution of resistance and its effects in various contexts.
In the epidemiology literature, a number of papers have shown
that using a variety of drugs in a population has better drug-
resistance outcomes than using a single drug. A key question in
such studies has been to determine how multiple drugs should be
deployed, whether as (1) combination therapy, (2) cycling the
drugs on a ﬁxed schedule, (3) cycling on an adaptive schedule, or
(4) distributing all drugs simultaneously (“mixing”). The earliest
attempt, known to us, that considered the deployment of multiple
antimalarial drugs in a population was a simple mathematical model
described by [15]. The authors compared combination therapy to
cycling individual drugs, and showed that the relative beneﬁts of
either strategy depend on the parasite recombination rate and drug
coverage in the population. Bonhoeffer et al. [8] analyzed a general
two-drug resistance model and concluded that cycling strategies
fared worse than mixing strategies or combination therapies, when
considering the total number of future cases of disease prevented.
Bergstrom et al. [6] show that mixing drugs has an inherent advan-
tage over cycling because mixing creates a more variable environ-
ment where drug-resistance evolution is less favored and slower for
the disease in question. Smith et al. [37] show that a strategy of using
multiple drugs can delay or even prevent drug-resistance evolution,
whether the drugs are distributed by location, or whether multiple
drugs are used in each location. However, this balanced system is
sensitive to non-compliance; if spatial coupling is strong and if one
location chooses a more selﬁsh strategy, this can have adverse effects
on other locations. Boni et al. [10] show that cycling regimes create a
resistance-friendly environment earlier than mixing regimes; this
study focuses on malaria transmission and shows through extensive
numerical simulations that using multiple ﬁrst-line therapies (MFT)
simultaneously outperforms many types of cycling strategies.
3. Disease transmission and resistance evolution
While treatment homogeneity is valued by health policy experts
and limited drug choice has many operational advantages, such a
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this paper we consider the case of infectious diseases that are
curable by some drug or therapy. Selection pressure imposed by the
use of any single drug sooner or later leads to the evolution of
resistance to that drug. Two social externalities inherently charac-
terize the treatment of infectious diseases. On the one positive side,
treatment cures the patient, thereby preventing the disease from
being transmitted to other individuals. On the negative side, drug
treatment selects in favor of mutations that confer drug resistance,
increasing the likelihood that the drug will be less effective in the
future. The individual patient fails to consider either of these ex-
ternalities when deciding whether or not to receive a treatment.
3.1. Disease transmission model
A simple disease transmission model that includes compart-
ments for susceptible, infected with resistant strain or drug-
susceptible strain, can be used to understand how drug variety
impacts resistance and disease burden. A basic model for a single
drug, two and three drugs is presented in Appendix. Despite the
parsimony of this disease transmission and resistance evolution
model, for cases involving more than 3 drugs the number of dif-
ferential equations required to deﬁne the system becomes very
large. The number of equations increases exponentially in the
number of drugs employed simultaneously in the population.
It is not possible to derive an analytical expression of disease
prevalence and total resistance as a function of the number of drugs n
used to treat the disease. The reason why is that the system of
equations needed to describe the dynamics of the disease and to
derive the analytical expressions of interest changeswith the number
of available drugs. We therefore proceed with building a simulation
model and rely on numerical solution of such an ODE system to
approximate the functions of interest, under various disease settings.
In order to incorporate more epidemiological realism into the
analysis, we employ the malaria transmission model described by
[10] (equations (A1)e(A5) in supplementary materials of [10]). This
model is an ODE system that scales with size depending on the
numberof drugsbeingused; in this analysiswe consider amaximum
of ten drugs. The model accounts for immunity to malaria, allowing
slow waning and acquisition of immunity for individuals that are
infected a long time. Hosts can be in symptomatic or asymptomatic
states, with only symptomatic hosts receiving treatment. The model
tracks the circulation of all drug resistant and multi-drug resistant
types to the tendrugs in themodel,1024 in total. Strains resistant to a
single drug have a 1% ﬁtness cost of resistance, and an additional 1%
ﬁtness cost is imposed for resistance to each additional drug. The
multi-drug resistant strainwith resistance to all ten drugs is 9.6% less
ﬁt than the sensitive wildtype strain.
We calibrated the model to four endemicity scenarios, with
equilibrium prevalences set to 0.1% (very low), 0.5% (low), 5.0%
(moderate), 25% (high). Equilibrium prevalences are obtained by
determining the prevalence at endemic equilibrium when 50% of
the population is treated with an effective drug, in the absence of
resistance evolution. Because our calculated prevalences are not
age-speciﬁc, they do not have an exact correspondence to the
classical epidemiological classiﬁcations of malaria as hypoendemic,
mesoendemic, hyperendemic, or holoendemic.
3.2. Disease burden and cost of resistance
For assessing the resistance burden under each scenario and
therefore quantifying the cost associated with it, disability-
adjusted life years (DALYs) are used [30,31]. The DALY is a widely
used measure of overall disease burden in the ﬁeld of public health
and health impact assessment and combines the time lived withdisability and the time lost due to premature mortality. It is deﬁned
as DALY¼ YLLþYLD, where YLL denotes the years of life lost due to
premature mortality and YLD the years lived with disability [43].
The term “disability” is used broadly to refer to departures from
good or ideal health in any of the important domains of health,
following the standard terminology used to deﬁne global burden of
disease. Social preferences for the point in time or age at which a
death or disability occurs can be incorporated into DALY calcula-
tions, but for simplicity reasons we will assume that a healthy year
now is equally preferred to a healthy year in the future (no dis-
counting health with time) and that the value of each year of life
does not depend on age (no social weighting).
In our context, we do not consider different death rates between
infected population with a susceptible strain and infected with a
strain resistant to a drug. Therefore disease and resistance burden
are captured through the differences under each treatment sce-
nario of disease prevalence and of treatment failures due to resis-
tance emergence and spread.
Prevalence (PR) is deﬁned as the total fraction of the population
that is infected with any type of strain. Let n be the number of drugs
employed simultaneously in the population,W denote the fraction
of the population that is infected with a susceptible strain and Xk
the fraction of the population that is infected with a strain resistant
to drug or drug combination k. Then prevalence at a ﬁxed time t is
given by:
PRðnÞ ¼
X
k˛T
Xk þW
where T is the set of all subsets of n. We deﬁne total resistance (TR)
at a given time t as:
TRðnÞ ¼
Xn
i¼1
i
n
gi
where gi is the fraction of all infected individuals that are infected
with a strain resistant to exactly i drugs. Total resistance is a
number between zero and one, and it is the probability that, a
randomly chosen parasite would be resistant to a randomly chosen
drug. Let fi be the fraction of patients treated with drug i,
i ¼ 1,2,.,n. The Number of Treatment Failures (NTF) due to resis-
tance are given by the expression:
NTFðnÞ ¼ PRðnÞ$TRðnÞ$
Xn
i¼1
fi
Therefore, Disease Burden (DB) up to time t (time when the
policy is evaluated) is given by the expression:
DBðn; tÞ ¼
Zt
0
PRðn; tÞ$
" 
1
Xn
i¼1
fi
!
þ TRðn; tÞ$
Xn
i¼1
fi
#
$D$Sdt
where D is the average time of being sick when the patient receives
no treatment or the treatment fails and S is a weight factor that
reﬂects the severity of the disease into consideration. Note that the
units of the disease burden are DALYs lost. By deﬁning V as the
value of one lost year of “healthy” life, usually mentioned in the
literature as the value of a life year (VLY), we can deﬁne the Cost of
Disease Burden: CDB(n,t) ¼ DALYs $V.
We proceed with approximating the functions of interest, under
various disease settings, based on the results of our simulation
model.
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Disease burden can be decomposed in two main parts: the
burden due to infections with drug resistant organisms being
treated with ineffective drugs (“resistance burden”) and the burden
due to the individuals not receiving treatment at all (“untreated
burden”). The impact of drug resistance is captured through the
cumulative number of treatment failures up to time t, when the
policy is evaluated, while the impact of the disease progress and the
untreated burden through the cumulative prevalence of the disease.
We ran simulations for different endemicity settings in order to
estimate these quantities as a function of n, at different time points.
Resistance Burden. Simulation results for all endemicity settings,
suggest that the NTF, evaluated at time t ¼ 5, t ¼ 10, t ¼ 15 and
t ¼ 20, is decreasing exponentially with the number of available
drugs. In all cases, for ﬁxed t,
R t
0 PRðn; tÞ$TRðn; tÞdt can be very well
approximated by an exponential function of n (using Stata/SE v10.0,
goodness of ﬁt - R2 - is higher than 0.98 in all cases). By ﬁtting the
simulation results, as shown in Fig. 1, we get:
Zt
0
PRðn; tÞ$TRðn; tÞdtxb0eb1n
where b0 > 0 and b1 < 0.
Untreated burden. For given t, simulation results of cumulative
prevalence of the disease suggest that it is a monotonicallyFig. 1. Exponential ﬁt of NTF for a givendecreasing and convex function in n. Thus, cumulative prevalence
can be well approximated well by rational function of n [35]. Fig. 2
presents the simulation and curve ﬁtting results for a second order
rational function. The approximation is very good (goodness of ﬁt -
R2 - is higher than 0.96 in all cases) and therefore we have evidence
that:
Zt
0
PRðn; tÞdtx b0 þ b1n
1þ b2nþ b3n2
where bi (i¼ 0,1,2,3) are constants that depend on both the point in
time when cumulative prevalence is evaluated and the endemicity
setting.
Both resistance burden and disease prevalence are mono-
tonically decreasing functions in n and consequently total disease
burden decreases with drug variety. On the other hand, a wider
drug assortment has cost implications on the supply chain; this is
the topic of the next section.4. Directional effects of higher variety in the supply chain
In this sectionwe argue that for a given service level the number
of available drugs determines the procurement costs and also
safety stock holding costs. More speciﬁcally, we show that for a
ﬁxed number of procured treatments, higher drug variety leads to
an increase in purchasing and holding costs. When we incorporatet under various endemicity settings.
Fig. 2. Rational function ﬁt of cumulative prevalence for a given t under various endemicity settings.
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resistance containment, which determine the quantity of treat-
ments needed in future periods, higher drug variety does not
necessarily lead to an increase in purchasing and holding costs.
We begin by modeling procurement and safety stock holding
costs for one period under the assumption that demand and pro-
cured quantity is exogenous and ﬁxed. We deﬁne a period as the
time interval during which there is only one procurement oppor-
tunity. Then, we consider the multi-period case, where we incor-
porate the effect of number of drugs employed on future demand
for treatments. While the disease transmission model is a contin-
uous time model, operational costs are incurred per period (i.e. a
cycle), in discrete time. The following schematic ﬁgure shows the
correspondence (Fig. 3):4.1. Procurement cost per period
Volume discounts based on the total quantity purchased over a
given period are common in many industries, especially in
business-to-business transactions. In the pharmaceutical sector,
volume discounts are a common practice while in some cases na-
tional systems require price reductions if volume exceeds targetFig. 3. Time units.levels [16]. We consider the case of a linear discount dependent on
the total volume purchased applied to all units purchased.
Considering all unit quantity discounts, we model the unit price
of a drug i as a decreasing function of the quantity purchased qi per
period of time, i.e. ci(qi) ¼ c0kqi, where c0 and k are positive
constants and c0 > kQ, where Q is the total quantity procured per
period for treatments for a speciﬁc disease in a locus. Denoting by n
the number of available drugs for the same disease, total procure-
ment cost per period (PC) is deﬁned by: PCðnÞ ¼ Sni¼1½Fi þ ciðnÞqiðnÞ,
where Fi denotes the ﬁxed transaction cost per period for retaining
a relationship with a supplier and Sni¼1qiðnÞ ¼ Q . Assuming that all
available drugs are equally priced for the same volume levels or that
the least expensive ones (i.e. generics) are preferred, it follows
immediately that when the unit price is a decreasing function of the
quantity purchased andmoreover there is a ﬁxed transaction cost per
available drug per period, procurement cost is increasing with the
number of available drugs. In the special case where all available
drugs are used in equal proportions, the total procurement cost
function for a period can be re-written as PCðnÞ ¼ Sni¼1[Fi þ ciðQ=nÞ
ðQ=nÞ] ¼ Sni¼1Fi þ ðc0  kðQ=nÞÞðQ=nÞ ¼ nF þ ðc0  kðQ=nÞÞQ .4.2. Safety stock holding cost per period
Ensuring high product availability is of crucial importance in the
health sector. In the presence of supply and demand variability,
safety inventory is carried to satisfy any demand that exceeds the
forecasted needs. Raising the level of safety inventory though comes
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obsolescence, since shelf lives of drugs are often quite short.
Demand volatility for each drug increases with drug variety
because demand for each drug depends not only on the real pop-
ulation need for treatment but also on other factors like patients’
changing tastes or promotional efforts of pharmaceutical com-
panies. Forecasting accuracy decreases with higher drug variety, as
a result of lower demand aggregation. It is more difﬁcult to forecast
the demand for each individual drug than forecasting the need for
treatments in total for a certain disease. For any product, the narrower
the assortment, the higher is the pooling of the demand variability
and the lower the total safety inventory required, when the customer
service level is above 50% ([14]; p.318). Standard inventory theory
states that a narrower product assortment would lead to lower in-
ventory due to the beneﬁt of risk pooling as long as demands across
the different products are not perfectly positively correlated. Eppen
[20] with his seminal work showed that total holding and stockout
costs are lower when demand is aggregated, for independent and
normal demand distributions and identical cost parameters (one-
period setting). Eppen and Schrage [21] extend the result for the
multiple period problemwhile [13] generalize Eppen’smodel tomore
general multivariate dependent demand distributions.
For the sake of simplicity, we assume that total demand for a
given period is normally distributed with mean D and variance s2,
available drugs n are used in equal proportions and there is no de-
mand correlation for drugs. The directional effects described by our
model and the insights we get do not depend on these assumptions.
In this case, thedemandperperiod foreachdrug i follows thenormal
distribution; NwðD=n; s2=nÞ. The required total safety stock, as a
function of n, is: SSðnÞ ¼ nF1ðCSLÞsL=
ﬃﬃﬃ
n
p
, where F1 is the inverse
of the standard normal distribution, sL is the total demand standard
deviation during the lead time and CSL the target service level
(probability of stockout during the replenishment period) [14]. Total
safety inventory holding cost per period is HCðnÞ ¼ hcF1ðCSLÞsL
ﬃﬃﬃ
n
p
,
where h is the holding cost per period and c the average unit cost of
employed drugs in the same period. As shown above, c is increasing
inn. Also,
ﬃﬃﬃ
n
p
is amonotonically increasing function. Thus, the cost of
holding safety inventory is increasing as drug assortment is
becoming wider. Total inventory held may increase or decrease
depending on the patient service level policy makers decide to
provide. In the case of substitutability, individual demands of
employed drugswill be negatively correlated. In this case, inventory
pooling beneﬁts will be even higher and the provided inventory
holding cost expression will serve as an upper bound.
Observation 1. Supply chain cost, deﬁned as the sum of pro-
curement and safety stock holding cost, is a monotonically
increasing concave function in the number of drugs employed
simultaneously in the population for a given time period, when
demand and procured quantity can be regarded as exogenous.
Proof:
By taking the ﬁrst and second derivatives with respect to n we
get:
dPCðnÞ
dn
¼ F þ k

Q
n
2
> 0
d2PCðnÞ
dn2
¼ 2kQ
2
n3
< 0
and,
dHCðnÞ
dn
¼ hF1ðCSLÞsL
ﬃﬃﬃ
n
p
c0ðnÞ þ hF1ðCSLÞsLc0ðnÞ
1
2
ﬃﬃﬃ
n
p > 0
given that c0ðnÞ ¼ kq0iðnÞ ¼ kQ=n2 > 0. The second order deriv-
ative is given by:d2HCðnÞ
2 ¼ 
a0ﬃﬃﬃﬃﬃ
3
p cðnÞ þ a
0ﬃﬃﬃp c0ðnÞ þ a0 ﬃﬃﬃnp c00ðnÞdn 4 n n
where a0 ¼ hF1ðCSLÞsL. Substituting c00ðnÞ ¼ 2kQ=n3 and after
some algebraic manipulation, we get:
d2HCðnÞ
dn2
¼ a
0kQﬃﬃﬃﬃﬃ
n5
p  a
0cðnÞ
4
ﬃﬃﬃﬃﬃ
n3
p < 0
Thus, both procurement and holding cost are monotonically
increasing, strictly concave functions in n. By deﬁning supply chain
cost SC(n) as the sum of procurement and holding cost, we have:
dSC(n)/dn > 0 and d2SC(n)/dn2 < 0. Supply chain cost, is an
increasing concave function in n, as the sum of two monotonically
increasing concave functions. Note that the deﬁnition of PC
0
(n) and
HC
0
(n) holds for n > 0, as the procurement and holding costs
functions, as deﬁned in our model, are discontinuous at n ¼ 0.
Assuming n is continuous random variable, as we move from n ¼ 0
to n ¼ 0 þ εwe treat from 0 a constant number of patients Q. In our
analysis, we are focusing on the issue of the optimal number of
drugs employed to treat a disease, and not on whether the disease
should be treated or not.
4.3. Multi-period case with endogenous demand
In this section, we consider a multi-period setting where de-
mand for treatment in future periods depends on the width of drug
assortment employed in a given period. As before, we compare the
beneﬁts of delayed and slower resistance evolution from a wider
drug assortment with operational costs, but the demand in future
periods (or quantity of treatments procured) is not exogenous or
ﬁxed but depends on the decisions on drug variety made in each
time period.
Simulation results suggest that disease burden, for a given t*,
can be expressed as:
DBðnÞ ¼
"
b0 þ b1$n
1þ b2$nþ b3$n2
 
1
Xn
i¼1
fi
!
þ b0eb1$n
Xn
i¼1
fi
#
$D$S
where b0,b1,b2,b3 are such that:
b1

1þ b2nþ b3n2
 ðb0 þ b1nÞðb2 þ 2b3nÞ
1þ b2nþ b3n2
2  0
and b0 > 0, b1 < 0. The above expression is a monotonically
decreasing convex function on n, as the weighted sum of two
decreasing convex functions.
According to our deﬁnition, disease burden for a period s is:
DBsðnÞ ¼
Zt
t1
PRðn; tÞ$
" 
1
Xn
i¼1
fi
!
þ TRðn; tÞ$
Xn
i¼1
fi
#
$D$Sdt
We model the total demand for treatments in period s as an
increasing function of disease prevalence in period s1and the total
procured quantity in period s, Qs, as an increasing function of de-
mand of the same period. We have: Ds ¼ H(PRs1(n)), Q s ¼ G(Ds)
and H0ðPRs1ðnÞÞ > 0, G0ðDsÞ > 0. Denoting by s* the number of
periods within t*, total procurement cost is given by:
PCðnÞ ¼
Xs
s¼1
Xn
i¼1
h
Fiþ ci;sðnÞqi;sðnÞ
i
¼ snFþ
Xs
s¼1

c0k
Qs
n

Qs

where the second equality holds for n identical drugs in terms of
cost parameters and usage. It is straightforward to see that ﬁxed
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increase or decrease as n increases. The total number of
sourced treatments over time decreases ðQ 0sðnÞ ¼ ðdGðDsÞ=dDsÞ
dHðDBs1Þ=dDBs1ÞðdDBs1ðnÞ=dnÞ < 0Þ. On the other hand, the
price per unit of sourced treatment increases in n ðdci;s=dn ¼
d=dn½c0  kQsðnÞ=n ¼ ðnkQ 0sðnÞ þ nkQsðnÞÞ=n2 > 0Þ.
The total safety stock holding cost for s* periods is given by the
expression:
HCðnÞ ¼
Xs
s¼1
hcsðnÞF1ðCSLÞsL;s
ﬃﬃﬃ
n
p ¼
Xs
s¼1
acsðnÞsL;s
ﬃﬃﬃ
n
p
where a ¼ hF1ðCSLÞ and csðnÞis the average unit cost in period s of
all drugs employed. It is reasonable to assume that standard devi-
ation of demand during lead time is proportional to the mean de-
mand of the same period (i.e. constant coefﬁcient of variation). We
therefore deﬁne s0L;sðDsÞ ¼ g, where g > 0. We note that as the
number of available drugs increases, both csðnÞ and
ﬃﬃﬃ
n
p
increase.
The standard deviation of demand during the lead time, however,
decreases with n as Ds is a decreasing function of n. Therefore,
depending on the speciﬁc parameters, safety stock holding costs
may increase or decrease as drug variety becomes wider.
Observation 2. When demand is endogenous and the procured
quantity of treatments per period is based on the level of disease
transmission and resistance evolution dynamics, supply chain cost
is not necessarily increasing on the number of available drugs.
It follows directly from the analysis above that while ﬁxed
procurement cost and the per unit price of the sourced treatments
increases, the total quantity to be procured decreases as drug va-
riety becomes wider due to the beneﬁt of disease and resistance
containment. Regarding safety stock, smaller drug variety on one
hand favors demand variability pooling but on the other hand in-
creases demand and thus its variability during the lead time. We
note that the total relevant cost function, deﬁned as the sum of
disease burden and supply chain cost, may not be unimodal in the
number of drugs employed simultaneously.
We show that for a given time horizon mixed treatment policies
with multiple drugs result in a better health outcome when
factoring in disease burden and resistance evolution. More inter-
estingly this additional beneﬁt is decreasing as the number of
available drugs increases. Increasing drug variety may come at an
operational cost though, increased procurement and holding costs.
Thus, for certain range of disease transmission and cost parameters
a clear trade-off will exist when deciding about the width of drug
assortment; there is a point beyond which the additional health
beneﬁt and the corresponding decrease in quantity of treatments
will not compensate for the increased operational costs fromhigher
drug variety. Policy makers in resource limited settings need to
explicitly consider this trade-off to achieve sustainable health
outcomes over a longer time horizon. In the next section we
conduct extensive numerical analysis to explore the endemicity
settings, drug prices and volume discount parameters where this
trade-off is most important to consider.
5. Numerical analysis
We begin our numerical analysis for a base population of one
million and for t ¼ 15 years. We use the international disability
weight for malaria1 for severity factor and we consider 20 days (it is
later varied from 5 to 30 days) as the average time of being sick
when there is no successful treatment. As for the value of one year1 Global burden of disease and risk factors: Table 3A.6, p120; disability weight by
disease and sequelae.of healthy life lost, there are still unresolved issues for estimating it
and the range of proposed values varies considerably among
studies [1] and countries. We are using the value of $1000 per DALY
implying a “health cost” of each untreated patient (ignoring ex-
ternalities) of about $12 (same magnitude as the average cost of a
treatment in the base case).
For an average drug price of $10 and a volume discount of 1% for
100,000 units, the total procurement cost is calculated. The ﬁxed
cost of ordering per supplier per period is set to $1000. The safety
stock needed to absorb ﬂuctuations in supply and demand is
calculated using standard deviation of demand during the lead time
equal to m/4, where m is the average demand per period. The
probability of a drug stock-out during the lead time is set to 5% and
an annual inventory holding cost of 15% is assumed. Fig. 4 shows
the results for the very low, low, medium and high endemicity
settings described in Section 3.1.
We observe that the total cost function, after the point where it
reaches its minimum, remains quite ﬂat as the number of drugs
increases. As expected, for low values of n, the cost of disease
burden decreases signiﬁcantly in the number of drugs employed
simultaneously due to the beneﬁt of resistance containment and
the decrease in disease prevalence. After a point though, it remains
quite ﬂat. This is because the marginal health beneﬁt of an addi-
tional drug is heavily decreasing as the width of variety increases,
as seen in Figs. 1 and 2. Procurement cost function behaves in a
similar way mainly because the number of sourced treatments
depends on disease prevalence. The rate at which procurement
costs decrease as n increases is lower than the rate of disease
burden decrease because higher variety leads to higher unit cost
per sourced treatment and higher ﬁxed costs. In accordance with
the analysis in Section 4.2, safety stock holding cost keeps
increasing as n increases, at a ﬂat rate, but its magnitude is small
compared to the other two cost components.
From the analysis in Section 4, it becomes apparent that the
behavior of supply chain costs depends heavily on the discount
scheme and the ﬁxed cost per supplier per period. For medium
endemicity setting and t ¼ 15, Fig. 5 presents how the various cost
elements behave as a function of n when the price of the drug is
high, when there are high volume discounts and when the ﬁxed
cost per supplier is very large.
When high volume discounts are applicable, procurement costs
increase and then decrease as variety increases. For example, when
we move from one to two different drugs, for a ﬁxed number of
treatments, the volume procured from each supplier reduces to
half. The potential price decrease based on volume is lost and, if
volume discount is high, it is not compensated by the fact that less
treatments are procured in total (due to the health beneﬁt associ-
ated with two compared to one drug). This trend is reversed as the
number of n increases because the potential gains from volume
discounts are decreasing. In the presence of very high ﬁxed cost per
sourced drug, procurement cost increases when the drug variety is
large and n is increasing. For high values of n, the ﬁxed costs, which
increase linearly in n, dominate the additional beneﬁt of sourcing
less treatments (which is decreasing as n increases). As expected,
when the price of the drug is high (compared to the health cost of
non-treating a patient), procurement cost is the main driver of total
cost. Similar behavior is observed for the other three endemicity
settings, while these effects become more pronounced the longer
the time horizon considered. For expositional purposes, we present
also the analogous results for high endemicity setting (Fig. 6).
The appropriate time horizon to be considered depends on the
disease under consideration and the expected time to the devel-
opment of next-generation drugs. All other things equal, we study
the effect of the chosen time horizon on the optimal number of
drugs to employ. For the base case described above, Fig. 7 shows, for
Fig. 4. Relevant costs as a function of drugs employed for different endemicity settings, p ¼ $10.
Fig. 5. Medium endemicity: Relevant costs as a function of drugs employed for different drug cost parameters (price, volume discount, ﬁxed cost).
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Fig. 6. High endemicity: Relevant costs as a function of drugs employed for different drug cost parameters (price, volume discount, ﬁxed cost).
Fig. 7. Average total cost per year when the time horizon varies.
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Table 2
Summary of notation.
Symbol Deﬁnition
B Birth rate
b Transmission rate constant
si Probability that de novo resistance emerges when drug i is used
r Rate at which treated individuals return to susceptible state
d Death rate
S Susceptible population
W Population infected with a susceptible strain
Xi Population infected with a strain that is resistant to drug i
I Infected population
fi Fraction of patients (symptomatic) who are treated with drug i,
i ¼ 1,2,..n
f0 Fraction of patients who are treated with no drug
n Number of drugs
Table 1
Optimal number of drugs: Left-hand column shows disease duration. Top row in
each table is the price of the drug; second row is the quantity discount.
* $1 $10 $100
0.1% 1.0% 10% 0.1% 1% 10% 0.1% 1% 10%
Very low endemicity
5 days 5 5 5 5 5 5 5 5 4
15 days 6 6 6 5 5 5 5 5 4
30 days 7 7 6 5 5 5 5 5 5
60 days 8 8 8 6 6 5 5 5 5
Low endemicity
5 days 5 5 5 5 5 5 5 5 4
15 days 6 6 6 5 5 5 5 5 4
30 days 7 7 6 5 5 5 5 5 5
60 days 8 8 8 6 6 5 5 5 5
Medium endemicity
5 days 6 6 5 5 5 5 5 5 5
15 days 7 7 6 6 6 5 5 5 5
30 days 7 7 7 6 6 5 5 5 5
60 days 9 9 8 6 6 6 5 5 5
High endemicity
5 days 6 6 5 5 5 5 5 5 1
15 days 7 7 7 5 5 5 5 5 1
30 days 9 9 8 6 6 5 5 5 4
60 days > ¼ 10 > ¼ 10 > ¼ 10 6 6 6 5 5 4
*All unit volume discount that result in 0.1%, 1% and 10% unit price reduction for
100,000 units bought.
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function behaves when the policy is evaluated at different time
points. In all cases, the longer the time horizon considered, the
larger the width of the optimal drug assortment.
We continue by employing a full factorial design to assess the
impact of the cost of the drug, the magnitude of the quantityFig. 8. Cost breakdown and optimal n for high endemicity settings when the codiscounts offered and the disease duration (by modifying the
average time of being sick when treatment fails) on the optimal
number of drugs. Table 1 summarizes the results of the analysis by
indicating the optimal number of drugs for each case and for t ¼ 10
years. (Table 2).
The results of the analysis are very similar under all four
endemicity scenarios; in some cases the number of optimal drugs
to be employed simultaneously is slightly higher in higher ende-
micity settings. Even if this may seem counterintuitive, it results
from the fact that the shape of the disease burden curve as a
function of the number of drugs n remains similar under all
endemicity settings. Disease prevalence seems to be a less impor-
tant factor when deciding about the width of drug assortment
compared to the disease duration. The only exception is when both
the price of the drug and the volume discount offered are very high.
The results show that in such a case, in the high endemicity sce-
nario, it may even be optimal to employ only one drug. This is not
the case under any other lower endemicity scenario.
For low and medium drug prices, the duration of disease when
there is no treatment or the treatment is ineffective, is a signiﬁcant
factor determining the optimal number of drugs. When the average
price of the drug is as small as $1, supply chain costs are of sec-
ondary importance. Especially when the severity of the disease is
high and endemicity is high, it is optimal to employ simultaneously
all available drugs. On the other hand, in the examples where the
drug price is $100, the optimal number of drugs depends less on the
severity of the disease and it even remains unchanged in the me-
dium endemicity setting. In such cases, procurement cost is the
main driver of total cost; a wider variety contains procurement
costs, up to a point, through themore effective disease containment
that results in less sourced treatments in total.
Volume price discounts have an effect on the optimal number of
drugs in the extreme case of high endemicity, high drug price and
high discount. The results show that when the price of the drug is
as high as $100, high volume discounts (that result in 10% price
reduction for 100,000 units procured) may reduce the optimal
number of drugs from 5 to 1 when disease endemicity is high. The
magnitude of the discount mainly determines the shape of the
procurement cost function (see Figs. 5 and 6).
We further explore this result - that it is optimal to employ only
one drug - by studying the cost breakdown structure, as a function
of n, for the case where the disease duration is 15 days (Fig. 8). We
compare the relevant cost functions with the case where disease
duration is increased to 30 days (optimal n in this case is 4) and the
case where volume discount per 100,000 is reduced to 1% (optimal
n is 5). We observe that for high discount, the total cost behavior is
similar when both the disease duration is 15 and 30 days: total cost
function has two local minima. The crucial difference is that forst of the drug is high: the effect of volume discounts and disease severity.
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global minimum is attained at n ¼ 1. When the disease severity is
higher (i.e. disease duration is 30 days) the local minimum at n ¼ 4
is also global minimum. On the contrary, when volume discount is
lower, procurement cost, the main driver of total cost, is convex in
n: monotonically decreases up to n ¼ 5 and then starts increasing.
6. Discussion
Drug efﬁcacy is a public good that is threatened by the emer-
gence and spread of resistance. Available drugs for the treatment of
curable diseases should be used in a socially optimal way, explicitly
considering the negative externalities associated with use. Various
studies have argued that whenmore than one drug is employed in a
population at any given time, the emergence and spread of drug
resistance is delayed. In this paper, we compare the beneﬁts of
resistance and disease containment that may result from using a
wider drug assortment in a given population with the corre-
sponding increases in operational costs such as procurement and
inventory holding costs. We employ a simple general disease
transmission model that allows for treatment with more than one
drug to estimate the disease burden and cost of resistance. We
proceed by building a simulation model in order to numerically
approximate disease prevalence and total resistance, the two main
components of disease burden, as a function of the number of drugs
employed simultaneously. We show that disease burden (as
deﬁned in this paper) decreases with the number of drugs used. On
the other hand, for a given level of demand and procured quantity,
higher drug variety results in increased procurement cost when
volume discounts are present, and in increased safety stock holding
cost, when demand is uncertain. Drug variety at a given time also
impacts future demand because of disease expansion and resis-
tance evolution. When this effect of drug variety on future demand
is considered, then higher drug variety does not necessarily lead to
monotonically increasing procurement and safety stock holding
cost.
Large scale numerical analysis shows that when the severity of
the disease is high and the average price of the drugs is as small as
$1, it is optimal to simultaneously employ all available drugs. In
such cases supply chain related costs are very small as compared to
the disease burden related costs and it is always better to use more
drugs. This insight suggests that countries in sub-Saharan Africa
with high malaria burden should consider incorporating as many
available malaria medicines in their treatment guidelines and not
worry about the higher supply chain costs resulting from using a
wider assortment of drugs.
Only in some select instances when the disease endemicity is
high, the drugs are expensive (>$100), and manufacturers offer
signiﬁcant volume purchasing discounts it would be optimal to use
only one or very few of the available drugs. Infectious diseases with
expensive drugs and high endemicity include HIV/AIDS and MDR-
TB but the disease transmission and resistance development
model used in this paper does not directly apply to those diseases.
In all cases, the optimal width of drug assortment decreases
with the cost of the drugs. When drugs are cheaper it is optimal to
use most or all of the available drugs. For cheaper drugs, the
optimal variety increases with the disease duration. When drugs
are cheap the cost of disease burden is the main driver of total cost
and disease duration is an important component of the disease
burden. For more expensive drugs and/or when higher volume
discounts are available, the duration of the disease is of lesser
importance. The main reason is that the most signiﬁcant compo-
nent of total cost in this case is the cost of procuring the drugs.
Variable procurement cost may decrease with variety because the
number of sourced treatments is reduced. On the contrary, the unitprice and the ﬁxed cost dealing with each supplier increase with
the number of drugs employed simultaneously. Thus, when the
additional health beneﬁt of variety is small (around 5 drugs in our
examples) another drug is not justiﬁed; it leads to an increased unit
price and additional ﬁxed costs not compensated with the decrease
in the number of treatments sourced.
The numerical analysis also shows that compared to the dura-
tion of the disease and the price of the drugs, disease endemicity
appears to be a less important factor in determining the optimal
width of drug assortment. This implies that for a given disease e.g.
malaria the optimal drug assortment will be the same or at least
very similar across countries with varying levels of endemicity. This
greatly simpliﬁes the social planner’s problem and implies that
each country’s optimal assortment problem does not need to be
solved individually.
The model has several limitations. We assume that the diseases
considered do not inﬂuence the patients’ death rate and thus they
do not affect population dynamics. This may not be the case for
some infectious diseases with a very high associated mortality.
Furthermore, overall demand for drugs for some disease may be
affected by the assortment of drugs available. For given prevalence
that determines the size of the market (an upper bound of de-
mand), wider drug variety may lead to an increase of treatment
seeking, according to consumer theory. An interesting extension
and a topic of further research would be to incorporate the effect of
drug assortment on the fraction of the patients that seek treatment.
Procurement cost is often not a linear function of quantity as is
modeled in this paper. Hence, when this analysis is applied to a
speciﬁc situation, we need to be aware what part of the procure-
mentecost curve we are working with. For example, at a national
level, volume discounting may have a negligible effect if a country
decides to purchase three million instead of two million doses of a
drug. Similarly, supranational pooled purchasing arrangements
may eliminate some of the volume discount effects.
In this paper we assume that all available drugs are used in equal
proportions. However, it remains unclear what treatment guidelines
to healthcare providers can achieve this equal and uniform use of
multiple drugs. In addition, we need to be able to determine if
moderate deviations from a uniform distribution of drugs have small
or large effects on procurement costs, holding costs, and disease
burden. Boni et al. [10] show thatmodest deviations fromuniformity
should not lead to large increases in disease burden. Also, we do not
consider the costs associated with additional healthcare worker
training as a result of using a treatment protocol involving multiple
drugs. Although few estimates are available for this cost at present,
the cost of training health personnel could be signiﬁcant.
Finally, in many situations the number of drugs available to treat
a disease is very limited to start with. For instance, a country
managing its antimalarial supplywould realistically only consider the
simultaneous use of at most two or three drugs, given various
logistical challenges and the fact that only certain antimalarials
(artemisinin-combination therapies) are the most likely ones to be
used due to their high cure rates. The analysis conducted in this paper
may appear less relevant for such settings today but has high rele-
vance for policy makers as they think about future drug assortments.
Appendix
Simple disease transmission model
To take into consideration the externalities associated with the
treatment of infectious diseases and assess how disease spreads
and resistance emerges under various drug deployment policies,
we extend the simplest general disease model (SIS) [3,18] that al-
lows for treatmentwithmore than one different drug to include the
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models see [12,24]).
Assumptions
The main underlying assumptions of this model are the
following:
 Mass-action mixing. The contact rate between susceptible in-
dividuals and infected individuals is proportional to the prod-
uct of their respective densities.
 The transmission rate b is constant in time. This parameter
incorporates the expected number of contacts per unit of time
per individual and the probability of disease transmission.
 An infected individual becomes immediately infectious.
 No immunity. We consider here a disease that confers no im-
munity, or a very weak level of immunity on its host (in Section
3.1 we consider a malaria model where individuals can have
partial immunity to malaria).
 No ﬁtness cost of resistance. Typically, drug-resistant organ-
isms have a lower evolutionary ﬁtness than their drug-
sensitive counterparts, which can manifest itself as slightly
slower reproduction or quicker death [4,9]. In this version of
themodel, we do not account for the ﬁtness cost that resistance
imposes generally on the parasite.
 The susceptible population is constant. Most disease trans-
mission models have an endemic equilibrium state where the
birth of new susceptible is balanced by the loss of susceptible to
infection and death. For simplicity, in this section, we assume
that the susceptible population is constant.
This model for disease transmission and resistance evolution
when n drugs are employed simultaneously is presented sche-
matically in Fig. 9.
Population is divided into Susceptibles (S) and Infected with a
either a susceptible strain (W) or with a strain that is resistant to a
drug i (Xi) or drug combinations (Xij..n). The fraction of patients, all
symptomatic, that is treatedwith drug i is denoted by fi and f0 refers
to the fraction of the infected population that does not receive anyFig. 9. Disease transmission and resisttreatment. By deﬁnition,
Pn
i¼0fi ¼ 1. The rate at which treated
individuals return to susceptible state is r. Infected and susceptibles
die at a rate d and deaths are balanced by births into the uninfected
population (B denotes the birth rate).
A susceptible individual may either get infected by a drug-
sensitive strain or a strain resistant to any drug or drug combina-
tion at a rate b, which refers to the transmission rate constant, times
the fraction of population infected with the type of strain under
consideration. Infected patients that receive treatment return to
the susceptible state at a rate r provided that they are treated with
an effective drug. De novo resistance arises when an infected pa-
tient is treated with a drug; the rate of acquisition of de novo
resistance to drug i is rsi, where si denotes the probability that de
novo resistance emerges when drug i is used to treat an infected
patient. Resistance spreads when patients infected with a resistant
strain transmit it to the susceptible population.
The dynamics of this system are described mathematically
using ordinary differential equations (ODE). In the following sub-
sections we deﬁne the model for the case of one, two and three
drugs and we solve analytically for the density of each compart-
ment, which can be done because the susceptible population is
held constant.
A single drug used in the population
In case one drug at a time is used in the population under
consideration for a speciﬁc disease, the population is divided into:
the Susceptibles (S) (being held constant) and those Infected either
with susceptible strain (W) or a strain resistant to the drug (X).W(t)
and X(t) denote the fraction of the population that is infected with a
susceptible strain and a strain resistant to drug X at time t
respectively. Infected individuals with a susceptible strain that
receive treatment (f1), return to the susceptible state at rate r. Pa-
tients infected with a resistant strain (X) cannot be treated.
dXðtÞ
dt
¼ bXSþ s1f1rW  dX (1)ance evolution in case of n drugs.
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I ¼ W þ X (3)
The solution in case of just one drug is given by the following
expressions:
XðtÞ ¼ etðSbdÞc1 þ
	
etðSbdÞ  etðSbdf1rÞ


s1c2
WðtÞ ¼ etðSbdf1rÞc2
where c1 and c2 are constants determined by the initial conditions
of the system.
Two drugs simultaneously used in the population
When two drugs are used in fractions to treat infected popula-
tion (i ¼ 1,2), strains resistant to either of the two drugs or to both
arise and spread. The fraction of the population that is infectedwith
a strain resistant to both drugs cannot be treated effectively. The
system is described as follows:
dX1ðtÞ
dt
¼ bX1Sþ s1f1rW  rf2X1  dX1 (4)
dX2ðtÞ
dt
¼ bX2Sþ s2f2rW  rf1X2  dX2 (5)
dX12ðtÞ
dt
¼ bX12Sþ rðs1f1X2 þ s2f2X1Þ  dX12 (6)
dWðtÞ
dt
¼ bWS rðf1 þ f2ÞW  dW (7)I ¼ W þ X1 þ X2 þ X12 (8)
Solving the system, we get the following equations for the
fraction of population in each compartment at time t:
X1ðtÞ ¼ etðSbdrf2Þc1 þ
	
etðSbdrf2Þ  etðSbdrf1rf2Þ


c4s1
X2ðtÞ ¼ etðSbdrf1Þc2 þ
	
etðSbdrf1Þ  etðSbdrf1rf2Þ


c4s2
X12ðtÞ ¼ etðSbdÞc3 þ
	
etðSbdÞ  etðSbdrf1Þ


c2s1
þ
	
etðSbdÞ  etðSbdrf2Þ


c1s2
þ
	
etðSbdÞ  etðSbdrf1Þ  etðSbdrf2Þ
 etðSbdrf1rf2Þ


c4s1s2
WðtÞ ¼ etðSbdrf1rf2Þc4
Three drugs simultaneously used in the population
dX1ðtÞ
dt
¼ bX1Sþ s1f1rW  rðf2 þ f3ÞX1  dX1 (9)
dX2ðtÞ
dt
¼ bX2Sþ s2f2rW  rðf1 þ f3ÞX2  dX2 (10)
dX3ðtÞ
dt
¼ bX3Sþ s3f3rW  rðf1 þ f2ÞX3  dX3 (11)
dX12ðtÞ
dt
¼ bX12Sþ rðs1f1X2 þ s2f2X1Þ  rf3X12  dX12 (12)dX13ðtÞ
dt
¼ bX13Sþ rðs3f3X1 þ s1f1X3Þ  rf2X13  dX13 (13)dX23ðtÞ
dt
¼ bX23Sþ rðs3f3X2 þ s2f2X3Þ  rf1X23  dX23 (14)
dX123ðtÞ
dt
¼ bX123Sþrðs1f1X23þs2f2X13þs3f3X12ÞdX123 (15)
dWðtÞ
dt
¼ bWS rðf1 þ f2 þ f3ÞW  dW (16)
I ¼ W þ X1 þ X2 þ X3 þ X12 þ X23 þ X13 þ X123 (17)
The proportion of the population in each compartment at time t
is given by the following equations:
X1

t
¼ etðSbdrf2rf3Þc1þ	etðSbdrf2rf3ÞetðSbdrf1rf2rf3Þc8s1
X2

t
¼ etðSbdrf1rf3Þc2þ	etðSbdrf1rf3ÞetðSbdrf1rf2rf3Þc8s2
X3

t
¼ etðSbdrf1rf2Þc3þ	etðSbdrf1rf2ÞetðSbdrf1rf2rf3Þc8s3
X12ðtÞ ¼ etðSbdrf3Þc4 þ
	
etðSbdrf3Þ  etðSbdrf1rf3Þ


c2s1
þ
	
etðSbdrf3Þ  etðSbdrf2rf3Þ


c1s2 þ
	
etðSbdrf3Þ
 etðSbdrf1rf3Þ  etðSbdrf2rf3Þ
þ etðSbdrf1rf2rf3Þ


c8s1s2
X13ðtÞ ¼ etðSbdrf2Þc5 þ
	
etðSbdrf2Þ  etðSbdrf1rf2Þ


c3s1
þ
	
etðSbdrf2Þ  etðSbdrf2rf3Þ


c1s3 þ
	
etðSbdrf2Þ
 etðSbdrf1rf2Þ  etðSbdrf2rf3Þ
þ etðSbdrf1rf2rf3Þ


c8s1s3
X23ðtÞ ¼ etðSbdrf1Þc6 þ
	
etðSbdrf1Þ  etðSbdrf1rf2Þ


c3s2
þ
	
etðSbdrf1Þ  etðSbdrf1rf3Þ


c2s3 þ
	
etðSbdrf1Þ
 etðSbdrf1rf2Þ  etðSbdrf1rf3Þ
þ etðSbdrf1rf2rf3Þ


c8s2s3
X123ðtÞ ¼ etðSbdÞc7 þ
	
etðSbdÞ  etðSbdrf1Þ


c6s1 þ
	
etðSbdÞ
 etðSbdrf12


c5s2 þ
	
etðSbdÞ  etðSbdrf3Þ


c4s3
þ
	
etðSbdÞ  etðSbdrf1Þ  etðSbdrf2Þ
þ etðSbdrf1rf2Þ


c3s1s2 þ
	
etðSbdÞ  etðSbdrf1Þ
 etðSbdrf3Þ þ etðSbdrf1rf3Þ


c2s1s3 þ
	
etðSbdÞ
 etðSbdrf2Þ  etðSbdrf3Þ  etðSbdrf2rf3Þ


c1s2s3
þ
	
etðSbdÞ  etðSbdrf1Þ  etðSbdrf2Þ  etðSbdrf3Þ
þ etðSbdrf1rf2Þ þ etðSbdrf1rf3Þ þ etðSbdrf2rf3Þ
 þetðSbdrf1rf2rf3Þ


c8s1s2s3
WðtÞ ¼ etðSbdrf1rf2rf3Þc8
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system increases exponentially in the number of drugs employed
simultaneously in the population. We need to consider all possible
drug combinations that the strain may acquire resistance to, in
other words all the subsets of a set of cardinality n. Here we restrict
our analysis to maximum three drugs, that we consider as a rele-
vant number in the majority of cases. It follows directly from the
above analysis how one can extend the system of equations to
accommodate the case that the number of drugs used simulta-
neously against the same disease is larger than three.References
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